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abdominal, subhepatic. Histology: 36% lung (> NSCLC), 18% gastrointestinal adenocarcinomas (colon, pancreas, rectum, gall
bladder), 15% of melanomas, 10% endometrial sarcomas, breast CDI 6%, other: Chordoma, renal cell Ca or ducts of Bellini.
Results. Median GTV volume: 14 cc (1-1082), medium PTV Volume: 43 cc (7.2-1483). RT Techniques: IMRT-SS: 19 (2 IB) VMAT: 18
(10 SA, 8 DA), 2 IB; DART: 2 (9-12) and 28 RT-3D. Schemes as characteristics of the case, the most used: Liver: 8x7, 5Gy, Adrenal:
8x8Gy, Lung: 4x12Gy, Vertebrae: 4x6Gy or 5x6.25Gy. Tolerated the treatment without registration acute toxicity (RTOG). With a
mean follow up of 14 months (1-48) got 95% local control in patients (PET-CT), the exitus have been due to PD other levels. 4
patients lost and 2 p ongoing current SBRT (other locations),
Conclusions. SBRT has the potential to be used in place of surgery in high risk situations. Generally complete within a week or
two, not delaying systemic therapy that is so important for M1 patients. Even in incurable situations, SBRT may be used to local
control and disease symptoms to improve Quality of Life.
http://dx.doi.org/10.1016/j.rpor.2013.03.830
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Introduction. Stereotactic Body Radiotherapy (SBRT) is actually used in a wide variety of clinical situations. As single modality
therapy it can be used either as a radical treatment or in a palliative setting.
Objectives. We examined 66 patients treated with SBRT in our centers concerning initial diagnosis, treatment objective, clinical
outcomes and related toxicities.
Patients and Methods. Between 16-05-2011 and 28-02-2013, 22 patients were treated with radical intent for early stage no surgically
treated lung cancer, stage I 18 patients and stage II 4 patients. 10 patients were treated for metastatic liver disease, 25 patients
were treated for lung metastatic spread, and 9 patients treated for metastatic disease elsewhere in the body as part of their
palliative/symptomatic treatment.
Results. Lung cancer treatment schedules used were 48 Gy in 4 fractions or 60 Gy in 8 fractions, with a median 12 day treat-
ment time. Median follow-up was 8.3 months (1.2-20.3 months). Two radically treated lung cancer patients presented infectious
pulmonary disease within the ﬁrst three months after treatment. 14 patients presented measurable response/stable disease, 4
presented distant spread, according with RECIST criteria. Three patients at present time have not got follow-up data and 1 is
deceased. The remaining patients (stage IV/metastatic) were analyzed as an intent to treat objective.
Conclusions. All patients completed SBRT with low acute toxicity. Lung cancer patients radically treated presented adequate local
control according with RECIST criteria although further follow up time is needed. Metastatic patients presented good compliance
according with treatment objective.
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Introduction. Treating vestibular schwannoma (SV) may be surveillance, microsurgery or radiation.
Objectives. To evaluate the results of clinical local control, maintenance of hearing and at onset of complications of cranial nerves
V and VII, and the development of hydrocephalus and arachnoid cysts.
Method. Analyze the results of 167 patients treated with radiation (both radiosurgery (RC) or fractionated stereotactic RT (RTEF),
from 1997 to 2012.
Results. Mean follow-up is 6.7 years. Mean clinical months prior to diagnosis is 34 months. The hearing loss occurs in 95% of
cases, followed by balance disorders in 58% and 54% with tinnitus. Only 19% had useful hearing the diagnosis. The median dose
used was 12 Gy (range 7–17 Gy), prescribed to the isodose between 80-94%. The clinical local control was 97% at 5 years, 95% at
10 and 15 years. Hearing maintained in 67.8% of patients. Involvement of the permanent facial nerve occurs in 1.2%, and the
probability of toxicity of facial nerve was 5% at 5 years and 7% at 10 and 15 years. Involvement of the permanent trigeminal nerve
occurs in 2.4%, with a probability of involvement of 8% at 5, 10 and 15 years. Hydrocephalus occurs in 5% and the appearance of
aracnoid cyst was 6% at 5, 10 and 15 years.
Conclusions. The RC provides good local control results in the SV, comparable to the best surgical series, with a low risk of
complications.
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